alofanib (RPT835)

OM-RCA-01, a anti-FGFR1 humanized antibody, and alofanib, a FGFR2 allosteric inhibitor showed promising results in previous studies...Treatment with ipilimumab (ipi, 200 mcl on days 7, 10, and 13) was initiated in both cohorts when tumor volumes reached 70 mm3...The table summarizes the results of in vivo studies. Table: 1073P Conclusions Inhibition of FGFR1 and FGFR2 following immunotherapy resulted in a twofold suppression of tumor growth, especially in the CAFs+ cohort.

Alofanib showed acceptable tolerability and preliminary signs of clinical activity in the late-line treatment of metastatic gastric cancer. (ClinicalTrials.gov identifier: NCT04071184).

In further studies, the evaluation of FGFR2 amplification seems to be important. >

Alofanib was feasible and showed early signals of efficacy in heavily-pretreated patients with metastatic gastric cancer.

The MTD has not been reached and dose of 350 mg/m2 has been declared as RP2D. Alofanib showed acceptable tolerability and preliminary signs of clinical activity in the late-line treatment of metastatic gastric cancer.

The early biologic activity of alofanib in the late-line treatment of metastatic gastric cancer is encouraging. In addition to the above, any updated safety, PK, and efficacy data will be presented at the time of the AACR meeting.

PK profiles did not correlate with toxicity and efficacy of alofanib. The study is ongoing.

PK profiles did not correlate with toxicity and efficacy of alofanib. The study is ongoing.

Clinical trial information: NCT04071184. Research Funding: Skolkovo Foundation, Ruspharmtech